Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Debt Repayments (2016 - 2019)

Enanta Pharmaceuticals filings provide 5 years of Long-Term Debt Repayments readings, the most recent being $22000.0 for Q3 2019.

On a quarterly basis, Long-Term Debt Repayments rose 10.0% to $22000.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $86000.0, a 8.86% increase, with the full-year FY2019 number at $86000.0, up 8.86% from a year prior.
Long-Term Debt Repayments hit $22000.0 in Q3 2019 for Enanta Pharmaceuticals, roughly flat from $22000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $22000.0 in Q2 2019 to a low of $16000.0 in Q4 2015.
Median Long-Term Debt Repayments over the past 5 years was $19000.0 (2017), compared with a mean of $19125.0.
Biggest five-year swings in Long-Term Debt Repayments: grew 12.5% in 2016 and later increased 5.0% in 2019.
Enanta Pharmaceuticals' Long-Term Debt Repayments stood at $16000.0 in 2015, then grew by 12.5% to $18000.0 in 2016, then increased by 5.56% to $19000.0 in 2017, then grew by 10.53% to $21000.0 in 2018, then increased by 4.76% to $22000.0 in 2019.
The last three reported values for Long-Term Debt Repayments were $22000.0 (Q3 2019), $22000.0 (Q2 2019), and $21000.0 (Q1 2019) per Business Quant data.